Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death‐1 protein, were suggested in previous phase 1 studies. The present phase 2, single‐arm study (JAPIC‐CTI #111681) evaluated the antitumor activities of nivolumab and explored its predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Iizuka, Hajime, Uehara, Jiro, Otsuka, Fujio, Fujisawa, Yasuhiro, Takenouchi, Tatsuya, Isei, Taiki, Iwatsuki, Keiji, Uchi, Hiroshi, Ihn, Hironobu, Minami, Hironobu, Tahara, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448619/
https://www.ncbi.nlm.nih.gov/pubmed/28266140
http://dx.doi.org/10.1111/cas.13226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448619/
https://www.ncbi.nlm.nih.gov/pubmed/28266140
http://dx.doi.org/10.1111/cas.13226

Ejemplares similares